Baylin Technologies to acquire Alga Microwave for $27M
2018-06-28
Baylin Technologies Inc. (TSX: BYL) to acquire Alga Microwave Inc. for $27 million and to close $35M equity and debt bought deal financing led by Raymond James Ltd.
Second Cup closes $10M bought deal financing
2018-05-08
The Second Cup Ltd. (TSX: SCU) closed its short form prospectus offering of 2,898,600 common shares at $3.45 for gross proceeds of $10,000,170. Clarus Securities Inc. acted as sole underwriter and bookrunner.
Maple Leaf Green World announces $20M private placement
2018-05-04
Maple Leaf Green World (NEO: MGW; OTCQB: MGWFF) engaged Emerging Equities Inc. for a brokered private placement financing for gross proceeds of a minimum of $1,000,000 and a maximum of $20,000,000
Akumin completes US $35M bought deal financing
2018-05-02
Akumin Inc. (TSX: AKU.U) completed bought deal offering of 8,750,000 common shares at US $4.00 for gross proceeds of US $35,000,000. Clarus Securities Inc. led the offering.
Goodfood Market announces $10M bought deal
2018-04-18
Goodfood Market (TSX: FOOD) engaged GMP Securities L.P. for a bought deal of 4 million common shares at $2.50 per shares for gross proceeds of approximately $10 million
AcuityAds Holdings closes $4.6M bought deal
2018-04-17
AcuityAds Holdings Inc. (TSX-V:AT) closed bought deal private placement of 4,600,000 shares at $1.00 for gross proceeds of $4.6 million. Haywood Securities Inc. led the offering
Akumin announces US $35M bought deal
2018-04-11
Akumin (TSX: AKU.U) engaged Clarus Securities Inc. for a bought deal of 8,750,000 Common Shares at US $4.00 for gross proceeds of US $35,000,000
DiaMedica Therapeutics closes US $2.5M final tranche of private placemet
2018-03-29
DiaMedica Therapeutics (TSX-V: DMA; OTCQB: DMCAF) closed second and final tranche of offering for gross proceeds of approximately US$2.5M. The company raised US $6.3M in two tranches.
Xenon Pharmaceuticals closes Teva and BVF transactions
2018-03-28
Xenon Pharmaceuticals (NASDAQ: XENE) terminated collaborative development and license agreement with Teva Pharmaceuticals and closed share exchange transaction with Biotechnology Value Fund (BVF)
Solarvest BioEnergy closes private placement
2018-03-26
Solarvest BioEnergy Inc. (TSX-V: SVS) closed previously announced financing, issuing convertible debentures units for the aggregate gross proceeds of $1,000,000.
